Overview

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.
Phase:
Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.